Details of the Drug Combinations

General Information of This Drug (ID: DMBESUA)

Drug Name

Tucatinib DMBESUA

Synonyms

Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE

Indication

Disease Entry	ICD 11	Status	REF
HER2-positive breast cancer	2C60-2C65	Approved	[1]
Gastric adenocarcinoma	2B72	Phase 2/3	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

10 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Fulvestrant + Tucatinib	DC24EA7	Fulvestrant	Anatomic Stage II Breast Cancer AJCC v8	[3]
Fulvestrant + Tucatinib	DCMDIAN	Fulvestrant	HER2-positive Metastatic Breast Cancer	[4]
Rifampicin + Tucatinib	DCDEWWJ	Rifampicin	Drug-drug Interaction	[5]
Tucatinib + LEE011	DC3GOV2	LEE011	Anatomic Stage II Breast Cancer AJCC v8	[3]
Tucatinib + Capecitabine	DC46KGK	Capecitabine	HER2 Positive Metastatic Breast Cancers	[6]
Tucatinib + Osimertinib	DC4LLXV	Osimertinib	Metastatic Lung Non-Small Cell Carcinoma	[7]
Tucatinib + Digoxin	DCOZDF9	Digoxin	Drug-drug Interaction	[5]
Tucatinib + Gemfibrozil	DCSE08L	Gemfibrozil	Drug-drug Interaction	[5]
Tucatinib + Itraconazole	DCX8YWU	Itraconazole	Drug-drug Interaction	[5]
Tucatinib + Capecitabine	DC50TGP	Capecitabine	Breast Cancer	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 DrugCom(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	ClinicalTrials.gov (NCT04499924) Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02). U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT05319873) Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
4	ClinicalTrials.gov (NCT05230810) Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
5	ClinicalTrials.gov (NCT03723395) A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
6	ClinicalTrials.gov (NCT02025192) A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
7	ClinicalTrials.gov (NCT06067776) Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
8	ClinicalTrials.gov (NCT04721977) A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)